^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FLX925

    i
    Other names: FLX925, AMG 925
    Associations

    News

    Trials
    Company:
    RAPT Therap
    Drug class:
    CDK4 inhibitor, CDK6 inhibitor, FLT3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. (PubMed, Ann Hematol)
    Mass cytometry identified pathways that may confer resistance to AMG925 in phenotypically defined AML stem/progenitor cells and demonstrated that combined blockade of FLT3-CDK4/6 and AKT/mTOR signaling facilitated stem cell death. Our findings provide a rationale for the mechanism-based inhibition of FLT3-CDK4/6 and for combinatorial approaches to improve the efficacy of FLT3 inhibition in both FLT3 wild-type and FLT3-mutated AML.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CDK4 (Cyclin-dependent kinase 4)
    |
    FLT3 mutation
    |
    FLX925